Gapping down
In reaction to disappointing earnings/guidance:ACXM -9.5%, BRCD -3%, MRVL -2.8%, HIBB -2.7%, TFM -0.8%,
Other news: OTIC -16.6% (reports Phase 2b topline data for OTO-104 in Meniere's Disease; 'Narrowly missed primary endpoint of reduction in vertigo frequency during Month 3 following treatment compared to a one month baseline period', Achieved statistical significance on multiple prospectively defined secondary endpoints), VGGL -15.9% ( announces proposed public offering of common stock; size not disclosed ), CVM -12.8% ( commenced an offering of common stock and warrants; terms not disclosed ), NVEE -6% (announces a public offering of common stock; size and price details not disclosed ), EHIC -2.8% (announces definitive agreements to sell up to ~22.34 mln common stock shares, at $12.00/ADS ), HAWK -1.1% (shareholders approved conversion into single class of common stock), .
Analyst comments: ESPR -3.3% (initiated with a Sell at Chardan Capital Markets; tgt $55), CONN -1.5% (downgraded to Perform from Outperform at Oppenheimer), LL -0.9% (target lowered to $18 from $30 at Piper Jaffray)
In reaction to disappointing earnings/guidance:ACXM -9.5%, BRCD -3%, MRVL -2.8%, HIBB -2.7%, TFM -0.8%,
Other news: OTIC -16.6% (reports Phase 2b topline data for OTO-104 in Meniere's Disease; 'Narrowly missed primary endpoint of reduction in vertigo frequency during Month 3 following treatment compared to a one month baseline period', Achieved statistical significance on multiple prospectively defined secondary endpoints), VGGL -15.9% ( announces proposed public offering of common stock; size not disclosed ), CVM -12.8% ( commenced an offering of common stock and warrants; terms not disclosed ), NVEE -6% (announces a public offering of common stock; size and price details not disclosed ), EHIC -2.8% (announces definitive agreements to sell up to ~22.34 mln common stock shares, at $12.00/ADS ), HAWK -1.1% (shareholders approved conversion into single class of common stock), .
Analyst comments: ESPR -3.3% (initiated with a Sell at Chardan Capital Markets; tgt $55), CONN -1.5% (downgraded to Perform from Outperform at Oppenheimer), LL -0.9% (target lowered to $18 from $30 at Piper Jaffray)